Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Pengfei Wang, Ryan G. Casner, Manoj S. Nair, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 5, pp. 747-751.e4
Open Access | Times Cited: 613

Showing 1-25 of 613 citing articles:

Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson, Michael Farzan, Bing Chen, et al.
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 1, pp. 3-20
Open Access | Times Cited: 2410
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Antibody evasion by the P.1 strain of SARS-CoV-2
Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, et al.
Cell (2021) Vol. 184, Iss. 11, pp. 2939-2954.e9
Open Access | Times Cited: 616
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Rigel Suzuki, Daichi Yamasoba, Izumi Kimura, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 700-705
Open Access | Times Cited: 616
COVID-19 pandemic
I Wayan Suryasa, María Rodríguez Gámez, Tihnov Koldoris
International Journal of Health Sciences (2021) Vol. 5, Iss. 2, pp. vi-ix
Open Access | Times Cited: 468
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
Felipe Gomes Naveca, Valdinete Alves do Nascimento, Victor Costa de Souza, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1230-1238
Open Access | Times Cited: 428
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
S. Gobeil, Katarzyna Janowska, Shana McDowell, et al.
Science (2021) Vol. 373, Iss. 6555
Open Access | Times Cited: 395
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Meng Yuan, Deli Huang, Chang‐Chun D. Lee, et al.
Science (2021) Vol. 373, Iss. 6556, pp. 818-823
Open Access | Times Cited: 362
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Jinhui Dong, Seth J. Zost, Allison J. Greaney, et al.
Nature Microbiology (2021) Vol. 6, Iss. 10, pp. 1233-1244
Open Access | Times Cited: 305
SARS-CoV-2 Variants of Concern
Jun Yong Choi, Davey M. Smith
Yonsei Medical Journal (2021) Vol. 62, Iss. 11, pp. 961-961
Open Access | Times Cited: 274
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 272
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rita E. Chen, Emma S. Winkler, James Brett Case, et al.
Nature (2021) Vol. 596, Iss. 7870, pp. 103-108
Open Access | Times Cited: 251
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
Barak Mizrahi, Roni Lotan, Nir Kalkstein, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 250
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Daniel Martínez-Flores, Jesús Zepeda–Cervantes, Adolfo Cruz-Reséndiz, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 211
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 204
Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
Chee Wah Tan, Wanni Chia, Barnaby Edward Young, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1401-1406
Open Access | Times Cited: 203
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 635
Open Access | Times Cited: 191
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
Ivana Lazarević, Vera Pravica, Danijela Miljanovic, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1192-1192
Open Access | Times Cited: 183
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, et al.
Cell Reports (2021) Vol. 38, Iss. 2, pp. 110218-110218
Open Access | Times Cited: 180
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 174
Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe
Vikram Thakur, Shivam Bhola, Pryanka Thakur, et al.
Infection (2021) Vol. 50, Iss. 2, pp. 309-325
Open Access | Times Cited: 167
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
Yaniv Lustig, Neta S. Zuckerman, Ital Nemet, et al.
Eurosurveillance (2021) Vol. 26, Iss. 26
Open Access | Times Cited: 158
Page 1 - Next Page

Scroll to top